DOP2019000102A - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents

Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Info

Publication number
DOP2019000102A
DOP2019000102A DO2019000102A DO2019000102A DOP2019000102A DO P2019000102 A DOP2019000102 A DO P2019000102A DO 2019000102 A DO2019000102 A DO 2019000102A DO 2019000102 A DO2019000102 A DO 2019000102A DO P2019000102 A DOP2019000102 A DO P2019000102A
Authority
DO
Dominican Republic
Prior art keywords
staphylococcus
infections caused
against infections
vaccine constructs
uses against
Prior art date
Application number
DO2019000102A
Other languages
English (en)
Spanish (es)
Inventor
Malouin Francois
Ster Celine
Cote-Gravel Julie
Brouillette Eric
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of DOP2019000102A publication Critical patent/DOP2019000102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DO2019000102A 2016-10-21 2019-04-17 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus DOP2019000102A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21

Publications (1)

Publication Number Publication Date
DOP2019000102A true DOP2019000102A (es) 2019-07-15

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000102A DOP2019000102A (es) 2016-10-21 2019-04-17 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Country Status (24)

Country Link
US (2) US11324815B2 (OSRAM)
EP (1) EP3529260A4 (OSRAM)
JP (2) JP7181208B2 (OSRAM)
KR (1) KR20190082229A (OSRAM)
CN (1) CN109843910A (OSRAM)
AR (1) AR109847A1 (OSRAM)
AU (2) AU2017346974B2 (OSRAM)
BR (1) BR112019007796A2 (OSRAM)
CA (1) CA3037070A1 (OSRAM)
CL (1) CL2019001048A1 (OSRAM)
CO (1) CO2019005169A2 (OSRAM)
CR (1) CR20190249A (OSRAM)
DO (1) DOP2019000102A (OSRAM)
IL (1) IL265869A (OSRAM)
MX (2) MX2019004539A (OSRAM)
MY (1) MY195369A (OSRAM)
NZ (1) NZ751880A (OSRAM)
PE (1) PE20191320A1 (OSRAM)
PH (1) PH12019500843A1 (OSRAM)
RU (2) RU2022100889A (OSRAM)
SG (2) SG10201912431XA (OSRAM)
TW (1) TW201819402A (OSRAM)
UY (1) UY37448A (OSRAM)
WO (1) WO2018072031A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777317A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
US20220185852A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
WO2026014994A1 (ko) * 2024-07-12 2026-01-15 주식회사 더윤헬스텍 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288774C (en) 1985-01-07 1991-09-10 Deborah A. Eppstein 1,2-dialkoxy-w-trialkylammonium cationic surfactants
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
BRPI0516974A (pt) * 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
KR100729954B1 (ko) 2004-12-01 2007-06-20 주식회사 엘지생명과학 Sec1 변이 단백질의 제형 및 그것의 제형화 방법
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2411046B1 (en) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
CA2792956C (en) * 2010-03-17 2021-11-16 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof
BR112013032774B1 (pt) 2011-06-19 2020-05-05 Univ New York composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso

Also Published As

Publication number Publication date
JP2019531100A (ja) 2019-10-31
CO2019005169A2 (es) 2019-08-09
RU2019115303A3 (OSRAM) 2021-03-02
MY195369A (en) 2023-01-16
AU2017346974A1 (en) 2019-03-14
KR20190082229A (ko) 2019-07-09
AU2017346974B2 (en) 2022-03-31
JP2023025066A (ja) 2023-02-21
EP3529260A1 (en) 2019-08-28
MX2023001219A (es) 2023-03-03
RU2766354C2 (ru) 2022-03-15
AU2022204585A1 (en) 2022-07-21
TW201819402A (zh) 2018-06-01
JP7181208B2 (ja) 2022-11-30
AR109847A1 (es) 2019-01-30
PH12019500843A1 (en) 2019-12-02
US20220288183A1 (en) 2022-09-15
PE20191320A1 (es) 2019-09-24
CR20190249A (es) 2019-10-16
WO2018072031A1 (en) 2018-04-26
US11324815B2 (en) 2022-05-10
UY37448A (es) 2018-03-23
CA3037070A1 (en) 2018-04-26
EP3529260A4 (en) 2020-12-16
BR112019007796A2 (pt) 2019-09-03
RU2019115303A (ru) 2020-11-23
CL2019001048A1 (es) 2019-08-30
IL265869A (en) 2019-06-30
SG11201901483QA (en) 2019-03-28
CN109843910A (zh) 2019-06-04
SG10201912431XA (en) 2020-02-27
NZ751880A (en) 2023-04-28
US20190216913A1 (en) 2019-07-18
MX2019004539A (es) 2019-06-12
RU2022100889A (ru) 2022-04-06

Similar Documents

Publication Publication Date Title
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2017013709A2 (es) Lactamas bicíclicas.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
DOP2017000298A (es) Reguladores de nrf2
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CO7400867A2 (es) Modificador del sabor dulce
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
DOP2016000145A (es) Reguladores de nrf2
MX2017001279A (es) Usos y composiciones de la flagelina.
CR20170336A (es) Compuestos de azolina sustituidos con un sistema de anillos condensados
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
CL2019001736A1 (es) Polimorfos.
CL2019001737A1 (es) Polimorfos.
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
CO2017006969A2 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado
PY18111999A (es) Hidroxiisoxazolinas y derivados de estos
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
NI202000042A (es) Polimorfos
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CR20180254A (es) Compuestos de imino con un sustituyente de 2-cloropirimidin-5-ilo como agentes de control de plagas
UY35707A (es) ?compuestos pirrolónicos, procesos e intermediarios para prepararlos, composiciones y métodos de uso?.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
CR20150641U (es) Composiciones farmacéuticas
PY1508111A (es) Polimorfos